Clinical trials: Hepatic Neoplasm
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Brain and Central Nervous System Tumors, Kidney Cancer
Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors
RATIONALE: Tubefeeding may help maintain good nutrition and lessen weight loss in younger patients receiving chemotherapy for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Leukemia, Liver Cancer
- Trial name
- NCT00624962
- Testing
- nutritional intervention, therapeutic nutritional supplementation
- Sponsor
- Vanderbilt University
HepatoCellular Carcinoma
Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
The purpose of this study is to evaluate the effect of liver-localised radioembolization and nivolumab on liver cancer.
- Trial name
- NCT03033446
- Testing
- Y-90 Radioembolization, Nivolumab
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma (HCC)
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma
The aim of this pilot study is to correlate the sorafenib plasma concentration to observed toxicity and to the disease control rate in 100 patients undergoing a palliative treatment of hepatocellular carcinoma (HCC).
- Trial name
- ACTES (NCT02834546)
- Testing
- Sorafenib plasma concentration 4 weeks after treatment initiation
- Where
- 5 sites in France
- Volunteers
- 143 people
- Sponsor
- University Hospital, Bordeaux
Hepatocellular Carcinoma
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
The investigators propose a phase II single-arm study on using stereotactic body radiation therapy in combination with durvalumab for inoperable/unresectable hepatocellular carcinoma.
- Trial name
- NCT04913480
- Testing
- Durvalumab, Stereotactic body radiation therapy
- Where
- Hong Kong
- Volunteers
- 37 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma
Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
N-acetylcysteine (NAC), a glutathione precursor and potent antioxidant, is known as a liver protector. As a steroid preparation, dexamethasone is known to have efficient anti-inflammation and immunosuppression effects.
- Trial name
- NCT06039280
- Testing
- N Acetylcysteine, Dexamethasone
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma (HCC)
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with…
- Trial name
- NCT06881446
- Where
- China
- Volunteers
- 2,651 people
- Sponsor
- Zhongda Hospital
Advanced Unresectable Hepatocellular Carcinoma
SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
This clinical study aims to evaluate the efficacy and safety of Retlirafusp alfa Injection (SHR-1701) combined with apatinib in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after…
- Trial name
- NCT07749859
- Testing
- Retlirafusp alfa Injection, apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Liver Cancer
Effects of Antiviral Therapy on HBV Reactivation
Hepatitis B virus (HBV) reactivation happens after liver resection for HBV-related hepatocellular carcinoma (HCC) patients, particularly for those with positive serum HBV-DNA .
- Trial name
- HBV-DNA(-) (NCT02829359)
- Testing
- Entecavir therapy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
DAA in the Risk of Recurrence After Curative Treatment of HCC
For early stage of HCC, surgical resection or radiofrequency ablation (RFA) is the mainstay curative treatments. However, recurrence is still a major issue after the surgery or RFA.
- Trial name
- NCT02959359
- Testing
- Ledipasvir 90mg/Sofosbuvir 400 mg, Ribavirin
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma
MicroRNAs as Diagnostic Biomarkers in Hepatocellular Carcinoma Among Somali Patients
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is the third leading cause of cancer that related death in the worldwide.
- Trial name
- NCT03227510
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- People's Friendship University of Russia
Prostatic Neoplasms
Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging - Protocol II
A new method for localization of the prostate during external beam radiotherapy. The method is based on insertion of a new thermo-expandable Ni-Ti stent.
- Trial name
- NCT00250224
- Testing
- Radiotherapy stent
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Aalborg University Hospital
Liver Tumours
Feasibility of Electromagnetic Acoustic Imaging of Liver Tumours
A single-centre, industry sponsored, proof-of-concept pilot study to assess the feasibility of Electromagnetic Acoustic Imaging (EMA) as an imaging platform in the visualization of hepatic tumours.
- Trial name
- NCT02827786
- Testing
- Electromagnetic Acoustic Imaging
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Enhanced Medical
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Advanced Malignancies and Hepatic Impairment
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver…
- Trial name
- NCT07422610
- Testing
- pelabresib
- Where
- 10 sites in France, Italy and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Surefire Precision Infusion System Registry
This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver…
- Trial name
- NCT02967523
- Testing
- DEB-TACE with Surefire Precision Infusion System
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- Surefire Medical, Inc.
Liver Cancer, Metastatic Cancer
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
RATIONALE: Heating melphalan to several degrees above body temperature and infusing it to the affected area directly around the tumor may kill more tumor cells.
- Trial name
- NCT00030082
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Non Small Cell Lung Cancer
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
- Conditions
- Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC)
- Trial name
- PSI-Immune (NCT07223424)
- Testing
- nivolumab, pembrolizumab
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- Diwakar Davar
Hepatocellular Carcinoma (HCC)
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
The purpose of this study is to assess the safety and effectiveness of treating a tumor using a different planning method called MCD for the FDA-Approved device, TheraSphere.
- Trial name
- ADVANCE-MCD (NCT07669727)
- Testing
- TheraSphere
- Volunteers
- 140 people
- Sponsor
- Boston Scientific Corporation
Liver Neoplasms
Fibroscan Predicts Complications After Hepatectomy
Most of the postoperative complications that may occur after hepatectomy are related to the underlying liver background, and the common preoperative tests do not completely predict such complications.
- Trial name
- Fibroscan (NCT02454686)
- Volunteers
- 240 people
- Sponsor
- University of Milan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.